Log in

Relevant bibliographies by topics / Lipid based delivery systems / Journal articles

Journal articles on the topic 'Lipid based delivery systems'

To see the other types of publications on this topic, follow the link: Lipid based delivery systems.

Author: Grafiati

Published: 10 December 2022

Last updated: 28 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Lipid based delivery systems.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Shrestha, Hina, Rajni Bala, and Sandeep Arora. "Lipid-Based Drug Delivery Systems." Journal of Pharmaceutics 2014 (May 19, 2014): 1–10. http://dx.doi.org/10.1155/2014/801820.

Full text

Abstract:

The principle objective of formulation of lipid-based drugs is to enhance their bioavailability. The use of lipids in drug delivery is no more a new trend now but is still the promising concept. Lipid-based drug delivery systems (LBDDS) are one of the emerging technologies designed to address challenges like the solubility and bioavailability of poorly water-soluble drugs. Lipid-based formulations can be tailored to meet a wide range of product requirements dictated by disease indication, route of administration, cost consideration, product stability, toxicity, and efficacy. These formulations are also a commercially viable strategy to formulate pharmaceuticals, for topical, oral, pulmonary, or parenteral delivery. In addition, lipid-based formulations have been shown to reduce the toxicity of various drugs by changing the biodistribution of the drug away from sensitive organs. However, the number of applications for lipid-based formulations has expanded as the nature and type of active drugs under investigation have become more varied. This paper mainly focuses on novel lipid-based formulations, namely, emulsions, vesicular systems, and lipid particulate systems and their subcategories as well as on their prominent applications in pharmaceutical drug delivery.

APA, Harvard, Vancouver, ISO, and other styles

2

Baca-Estrada, M. E., M. Foldvari, S. L. Babiuk, and L. A. Babiuk. "Vaccine delivery: lipid-based delivery systems." Journal of Biotechnology 83, no. 1-2 (September 2000): 91–104. http://dx.doi.org/10.1016/s0168-1656(00)00313-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

DONG, Wen-Juan, Yin-Jian ZHOU, and Wei LIANG. "Lipid-based siRNA Delivery Systems." PROGRESS IN BIOCHEMISTRY AND BIOPHYSICS 39, no. 5 (July 24, 2012): 396–401. http://dx.doi.org/10.3724/sp.j.1206.2012.00190.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Park, Joo Yeon, Mi-Gyeong Kim, Gayong Shim, and Yu-Kyoung Oh. "Lipid-based antigen delivery systems." Journal of Pharmaceutical Investigation 46, no. 4 (April 18, 2016): 295–304. http://dx.doi.org/10.1007/s40005-016-0246-z.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Limongi, Tania, Francesca Susa, Monica Marini, Marco Allione, Bruno Torre, Roberto Pisano, and Enzo di Fabrizio. "Lipid-Based Nanovesicular Drug Delivery Systems." Nanomaterials 11, no. 12 (December 14, 2021): 3391. http://dx.doi.org/10.3390/nano11123391.

Full text

Abstract:

In designing a new drug, considering the preferred route of administration, various requirements must be fulfilled. Active molecules pharmacokinetics should be reliable with a valuable drug profile as well as well-tolerated. Over the past 20 years, nanotechnologies have provided alternative and complementary solutions to those of an exclusively pharmaceutical chemical nature since scientists and clinicians invested in the optimization of materials and methods capable of regulating effective drug delivery at the nanometer scale. Among the many drug delivery carriers, lipid nano vesicular ones successfully support clinical candidates approaching such problems as insolubility, biodegradation, and difficulty in overcoming the skin and biological barriers such as the blood–brain one. In this review, the authors discussed the structure, the biochemical composition, and the drug delivery applications of lipid nanovesicular carriers, namely, niosomes, proniosomes, ethosomes, transferosomes, pharmacosomes, ufasomes, phytosomes, catanionic vesicles, and extracellular vesicles.

APA, Harvard, Vancouver, ISO, and other styles

6

Midoux, Patrick, and Chantal Pichon. "Lipid-based mRNA vaccine delivery systems." Expert Review of Vaccines 14, no. 2 (December 26, 2014): 221–34. http://dx.doi.org/10.1586/14760584.2015.986104.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Jain, Shikha, Vikas Jain, and S. C. Mahajan. "Lipid Based Vesicular Drug Delivery Systems." Advances in Pharmaceutics 2014 (September 2, 2014): 1–12. http://dx.doi.org/10.1155/2014/574673.

Full text

Abstract:

Vesicular drug delivery system can be defined as highly ordered assemblies consisting of one or more concentric bilayers formed as a result of self-assembling of amphiphilic building blocks in presence of water. Vesicular drug delivery systems are particularly important for targeted delivery of drugs because of their ability to localize the activity of drug at the site or organ of action thereby lowering its concentration at the other sites in body. Vesicular drug delivery system sustains drug action at a predetermined rate, relatively constant (zero order kinetics), efficient drug level in the body, and simultaneously minimizes the undesirable side effects. It can also localize drug action in the diseased tissue or organ by targeted drug delivery using carriers or chemical derivatization. Different types of pharmaceutical carriers such as polymeric micelles, particulate systems, and macro- and micromolecules are presented in the form of novel drug delivery system for targeted delivery of drugs. Particulate type carrier also known as colloidal carrier system, includes lipid particles, micro- and nanoparticles, micro- and nanospheres, polymeric micelles and vesicular systems like liposomes, sphingosomes, niosomes, transfersomes, aquasomes, ufasomes, and so forth.

APA, Harvard, Vancouver, ISO, and other styles

8

Kotta, Sabna, Navneet Sharma, Prateek Raturi, Mohd Aleem, and Rakesh Kumar Sharma. "Exploring Novel Strategies for Lipid-Based Drug Delivery." Journal of Nanotoxicology and Nanomedicine 3, no. 1 (January 2018): 1–22. http://dx.doi.org/10.4018/jnn.2018010101.

Full text

Abstract:

Currently, the concept of lipid-based drug delivery systems has gained much interest because of their capability to deliver drugs which dissolve sparingly in water or insoluble in nature. Several methods of lipid-based drug delivery exist, and each method has its own advantages as well as limitations. The primary objective of the formulation development is to improve the bioavailability of the drug. The nano-sized lipid-based drug delivery systems have enough potential to do so. This article addresses the various barriers to the transportation of drugs through certain routes and also the common excipients which used to develop the lipid-based drug delivery systems. It provides a thorough overview of the lipid formulation classification scheme (LFCS) and also deals with several formulation & evaluation aspects of lipid-based drug delivery system. Further, it focuses on the formulations which are already available in the market and their regulatory concerns, respectively.

APA, Harvard, Vancouver, ISO, and other styles

9

Chime, Salome A., Paul A. Akpa, and Anthony A. Attama. "The Utility of Lipids as Nanocarriers and Suitable Vehicle in Pharmaceutical Drug Delivery." Current Nanomaterials 4, no. 3 (November 11, 2019): 160–75. http://dx.doi.org/10.2174/2405461504666191016091827.

Full text

Abstract:

Lipid based excipients have gained popularity recently in the formulation of drugs in order to improve their pharmacokinetic profiles. For drugs belonging to the Biopharmaceutics Classification System (BCS) class II and IV, lipid excipients play vital roles in improving their pharmacokinetics properties. Various nanocarriers viz: Solid lipid nanoparticles, nanostructured lipid carriers, selfnanoemulsifying drug delivery systems (SNEDDS), nanoliposomes and liquid crystal nanoparticles have been employed as delivery systems for such drugs with evident successes. Lipid-based nanotechnology have been used to control the release of drugs and have utility for drug targeting and hence, have been used for the delivery of various anticancer drugs and for colon targeting. Drugs encapsulated in lipids have enhanced stability due to the protection they enjoy in the lipid core of these nanoformulations. However, lipid excipients could be influenced by factors which could affect the physicochemical properties of lipid-based drug delivery systems (LBDDS). These factors include the liquid crystalline phase transition, lipid crystallization and polymorphism amongst others. However, some of the physicochemical properties of lipids made them useful as nanocarriers in the formulation of various nanoformulations. Lipids form vesicles of bilayer which have been used to deliver drugs and are often referred to as liposomes and nanoliposomes. This work aims at reviewing the different classes of lipid excipients used in formulating LBDDS and nanoformulations. Also, some factors that influence the properties of lipids, different polymorphic forms in lipid excipients that made them effective nanocarriers in nano-drug delivery would be discussed. Special considerations in selecting lipid excipients used in formulating various forms of nanoformulations would be discussed.

APA, Harvard, Vancouver, ISO, and other styles

10

Dahiya, Sunita, and Rajiv Dahiya. "BIOAVAILABILITY ENHANCEMENT AND LIPID NANOCARRIER BASED DELIVERY OF PEPTIDES AND PROTEINS." Bulletin of Pharmaceutical Research 10, no. 1-3 (2020): 1–10. http://dx.doi.org/10.21276/bpr.2020.10.3.

Full text

Abstract:

Peptides and proteins are vital biomacromolecules that perform several bodily functions in various physiological and biological processes. Being biocompatible and biodegradable, these macromolecules are considered promising platforms for delivery of drugs and genes. However, peptides and proteins suffer from major limitations including enzymatic degradation, short circulation half-lives, and poor membrane permeability that leads to poor bioavailability, challenging their effective delivery. This article briefly discusses the inherent challenges in peptide and protein delivery along with strategies for bioavailability enhancement and lipid nanocarriers as prospective systems for peptide and protein drug delivery.

APA, Harvard, Vancouver, ISO, and other styles

11

Wong, Allan, and Istvan Toth. "Lipid, Sugar and Liposaccharide Based Delivery Systems." Current Medicinal Chemistry 8, no. 9 (July 1, 2001): 1123–36. http://dx.doi.org/10.2174/0929867013372535.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Esposito, P., I. Colombo, N. Coceani, D. Curto, and E. Chiellini. "Lipid-based nanoparticles as drug delivery systems." Journal of Pharmacy and Pharmacology 50, S9 (September 1998): 14. http://dx.doi.org/10.1111/j.2042-7158.1998.tb02214.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Mendonça, L. S., M. C. Pedroso de Lima, and S. Simões. "Targeted lipid-based systems for siRNA delivery." Journal of Drug Delivery Science and Technology 22, no. 1 (2012): 65–73. http://dx.doi.org/10.1016/s1773-2247(12)50006-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Chen, Yulin, Ping Ma, and Shuangying Gui. "Cubic and Hexagonal Liquid Crystals as Drug Delivery Systems." BioMed Research International 2014 (2014): 1–12. http://dx.doi.org/10.1155/2014/815981.

Full text

Abstract:

Lipids have been widely used as main constituents in various drug delivery systems, such as liposomes, solid lipid nanoparticles, nanostructured lipid carriers, and lipid-based lyotropic liquid crystals. Among them, lipid-based lyotropic liquid crystals have highly ordered, thermodynamically stable internal nanostructure, thereby offering the potential as a sustained drug release matrix. The intricate nanostructures of the cubic phase and hexagonal phase have been shown to provide diffusion controlled release of active pharmaceutical ingredients with a wide range of molecular weights and polarities. In addition, the biodegradable and biocompatible nature of lipids demonstrates the minimum toxicity and thus they are used for various routes of administration. Therefore, the research on lipid-based lyotropic liquid crystalline phases has attracted a lot of attention in recent years. This review will provide an overview of the lipids used to prepare cubic phase and hexagonal phase at physiological temperature, as well as the influencing factors on the phase transition of liquid crystals. In particular, the most current research progresses on cubic and hexagonal phases as drug delivery systems will be discussed.

APA, Harvard, Vancouver, ISO, and other styles

15

Kallem Sharat Venkat Reddy. "Clinical implications of novel polymer and lipid based drug delivery systems." International Journal of Research in Hospital and Clinical Pharmacy 2, no. 3 (September 24, 2020): 60–65. http://dx.doi.org/10.33974/ijrhcp.v2i3.232.

Full text

Abstract:

The use of lipids in drug delivery is not a new trend, some of the lipid dosage forms have been in use for a long time such as suppositories, creams, and emulsions. However, there has been much advancement in the designs of lipid carriers over the past decade. In the same way from the past two decades, new approaches in biodegradable and bio-reducible polymers have paved a way for many recent drug delivery systems. Applications of these novel drug delivery formulations have been promising clinically. However, each system has its pros and cons in various factors depending upon their use and intended route of administration. This review focuses on upbringing the challenges in the use of novel lipid and polymer drug delivery systems in clinical settings and few insights on how to overcome them.

APA, Harvard, Vancouver, ISO, and other styles

16

Berillo, Dmitriy, Adilkhan Yeskendir, Zharylkasyn Zharkinbekov, Kamila Raziyeva, and Arman Saparov. "Peptide-Based Drug Delivery Systems." Medicina 57, no. 11 (November 5, 2021): 1209. http://dx.doi.org/10.3390/medicina57111209.

Full text

Abstract:

Peptide-based drug delivery systems have many advantages when compared to synthetic systems in that they have better biocompatibility, biochemical and biophysical properties, lack of toxicity, controlled molecular weight via solid phase synthesis and purification. Lysosomes, solid lipid nanoparticles, dendrimers, polymeric micelles can be applied by intravenous administration, however they are of artificial nature and thus may induce side effects and possess lack of ability to penetrate the blood-brain barrier. An analysis of nontoxic drug delivery systems and an establishment of prospective trends in the development of drug delivery systems was needed. This review paper summarizes data, mainly from the past 5 years, devoted to the use of peptide-based carriers for delivery of various toxic drugs, mostly anticancer or drugs with limiting bioavailability. Peptide-based drug delivery platforms are utilized as peptide–drug conjugates, injectable biodegradable particles and depots for delivering small molecule pharmaceutical substances (500 Da) and therapeutic proteins. Controlled drug delivery systems that can effectively deliver anticancer and peptide-based drugs leading to accelerated recovery without significant side effects are discussed. Moreover, cell penetrating peptides and their molecular mechanisms as targeting peptides, as well as stimuli responsive (enzyme-responsive and pH-responsive) peptides and peptide-based self-assembly scaffolds are also reviewed.

APA, Harvard, Vancouver, ISO, and other styles

17

Filipczak, Nina, Satya Siva Kishan Yalamarty, Xiang Li, Muhammad Muzamil Khan, Farzana Parveen, and Vladimir Torchilin. "Lipid-Based Drug Delivery Systems in Regenerative Medicine." Materials 14, no. 18 (September 17, 2021): 5371. http://dx.doi.org/10.3390/ma14185371.

Full text

Abstract:

The most important goal of regenerative medicine is to repair, restore, and regenerate tissues and organs that have been damaged as a result of an injury, congenital defect or disease, as well as reversing the aging process of the body by utilizing its natural healing potential. Regenerative medicine utilizes products of cell therapy, as well as biomedical or tissue engineering, and is a huge field for development. In regenerative medicine, stem cells and growth factor are mainly used; thus, innovative drug delivery technologies are being studied for improved delivery. Drug delivery systems offer the protection of therapeutic proteins and peptides against proteolytic degradation where controlled delivery is achievable. Similarly, the delivery systems in combination with stem cells offer improvement of cell survival, differentiation, and engraftment. The present review summarizes the significance of biomaterials in tissue engineering and the importance of colloidal drug delivery systems in providing cells with a local environment that enables them to proliferate and differentiate efficiently, resulting in successful tissue regeneration.

APA, Harvard, Vancouver, ISO, and other styles

18

Jorgensen, Lene, Susana Martins, and Marco van de Weert. "Analysis of Protein Physical Stability in Lipid Based Delivery Systems—The Challenges of Lipid Drug Delivery Systems." Journal of Biomedical Nanotechnology 5, no. 4 (August 1, 2009): 401–8. http://dx.doi.org/10.1166/jbn.2009.1049.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Hussain, Afzal, Abdus Samad, Mohd Mohd Siddique, and Gajanand Sharma. "Lipid-Based Systems for Delivery of Biological Macromolecules." Recent Patents on Nanomedicine 5, no. 2 (July 27, 2015): 96–103. http://dx.doi.org/10.2174/1877912305666150616220223.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

L. Arias, J., B. Clares, M. E. Morales, V. Gallardo, and M. A. Ruiz. "Lipid-Based Drug Delivery Systems for Cancer Treatment." Current Drug Targets 12, no. 8 (July 1, 2011): 1151–65. http://dx.doi.org/10.2174/138945011795906570.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Gbian, Douweh Leyla, and Abdelwahab Omri. "Lipid-Based Drug Delivery Systems for Diseases Managements." Biomedicines 10, no. 9 (August 31, 2022): 2137. http://dx.doi.org/10.3390/biomedicines10092137.

Full text

Abstract:

Liposomes are tiny lipid-based vesicles composed of one or more lipid bilayers, which facilitate the encapsulation of hydrophilic, lipophilic, and amphiphilic biological active agents. The description of the physicochemical properties, formulation methods, characteristics, mechanisms of action, and large-scale manufacturing of liposomes as delivery systems are deeply discussed. The benefits, toxicity, and limitations of the use of liposomes in pharmacotherapeutics including in diagnostics, brain targeting, eye and cancer diseases, and in infections are provided. The experimental approaches that may reduce, or even bypass, the use of liposomal drug drawbacks is described. The application of liposomes in the treatment of numerous diseases is discussed.

APA, Harvard, Vancouver, ISO, and other styles

22

Blanchfield, J., and I. Toth. "Lipid, Sugar and Liposaccharide Based Delivery Systems 2." Current Medicinal Chemistry 11, no. 17 (September 1, 2004): 2375–82. http://dx.doi.org/10.2174/0929867043364621.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Uhríková, D., J. Teixeira, L. Hubčík, A. Búcsi, T. Kondela, T. Murugova, and O. I. Ivankov. "Lipid based drug delivery systems: Kinetics by SANS." Journal of Physics: Conference Series 848 (May 2017): 012007. http://dx.doi.org/10.1088/1742-6596/848/1/012007.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Wan, C., T. M. Allen, and P. R. Cullis. "Lipid nanoparticle delivery systems for siRNA-based therapeutics." Drug Delivery and Translational Research 4, no. 1 (June 28, 2013): 74–83. http://dx.doi.org/10.1007/s13346-013-0161-z.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Ljusberg-Wahren, Helena, Flemming Seier Nielsen, Mattias Brogård, Emma Troedsson, and Anette Müllertz. "Enzymatic characterization of lipid-based drug delivery systems." International Journal of Pharmaceutics 298, no. 2 (July 2005): 328–32. http://dx.doi.org/10.1016/j.ijpharm.2005.02.038.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Kalepu, Sandeep, Mohanvarma Manthina, and Veerabhadhraswamy Padavala. "Oral lipid-based drug delivery systems – an overview." Acta Pharmaceutica Sinica B 3, no. 6 (December 2013): 361–72. http://dx.doi.org/10.1016/j.apsb.2013.10.001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

NARENDER BOGGULA, VASUDHA BAKSHI, and HIMABINDU PEDDAPALLI. "An overview of lipid based vesicular systems: stability and regulatory considerations." GSC Biological and Pharmaceutical Sciences 21, no. 3 (December 30, 2022): 053–61. http://dx.doi.org/10.30574/gscbps.2022.21.3.0458.

Full text

Abstract:

Lipid based drug delivery systems are used to encapsulate the active substance within or interior space of the lipid bilayer. The lipid-based drug products are designed to improve the stability in-vivo and pharmacokinetics behavior of active substances. However, understanding of the factors that affect the stability is critical for rationale development of lipid based drug delivery systems with desired pharmacokinetics and bio-distribution. Lyophilization is one primary approach to improve the stability of lipid based systems. The article presents an overview of the characteristics of the lipid based drug delivery systems as drug carriers, particularly in relation to stability, regulatory considerations. Further, the present review emphasizes the formulation problems and marketed formulation of lipid-based systems.

APA, Harvard, Vancouver, ISO, and other styles

28

Zhao, Yan-Qi, Li-Jun Li, Er-Fen Zhou, Jiang-Yue Wang, Ying Wang, Lin-Miao Guo, and Xin-Xin Zhang. "Lipid-Based Nanocarrier Systems for Drug Delivery: Advances and Applications." Pharmaceutical Fronts 04, no. 02 (June 2022): e43-e60. http://dx.doi.org/10.1055/s-0042-1751036.

Full text

Abstract:

Lipid-based nanocarriers have been extensively investigated for drug delivery due to their advantages including biodegradability, biocompatibility, nontoxicity, and nonimmunogenicity. However, the shortcomings of traditional lipid-based nanocarriers such as insufficient targeting, capture by the reticuloendothelial system, and fast elimination limit the efficiency of drug delivery and therapeutic efficacy. Therefore, a series of multifunctional lipid-based nanocarriers have been developed to enhance the accumulation of drugs in the lesion site, aiming for improved diagnosis and treatment of various diseases. In this review, we summarized the advances and applications of lipid-based nanocarriers from traditional to novel functional lipid preparations, including liposomes, stimuli-responsive lipid-based nanocarriers, ionizable lipid nanoparticles, lipid hybrid nanocarriers, as well as biomembrane-camouflaged nanoparticles, and further discussed the challenges and prospects of this system. This exploration may give a complete idea viewing the lipid-based nanocarriers as a promising choice for drug delivery system, and fuel the advancement of pharmaceutical products by materials innovation and nanotechnology.

APA, Harvard, Vancouver, ISO, and other styles

29

Rethi, Lekshmi, Chinmaya Mutalik, Dito Anurogo, Long-Sheng Lu, Hsiu-Yi Chu, Sibidou Yougbaré, Tsung-Rong Kuo, Tsai-Mu Cheng, and Fu-Lun Chen. "Lipid-Based Nanomaterials for Drug Delivery Systems in Breast Cancer Therapy." Nanomaterials 12, no. 17 (August 26, 2022): 2948. http://dx.doi.org/10.3390/nano12172948.

Full text

Abstract:

Globally, breast cancer is one of the most prevalent diseases, inducing critical intimidation to human health. Lipid-based nanomaterials have been successfully demonstrated as drug carriers for breast cancer treatment. To date, the development of a better drug delivery system based on lipid nanomaterials is still urgent to make the treatment and diagnosis easily accessible to breast cancer patients. In a drug delivery system, lipid nanomaterials have revealed distinctive features, including high biocompatibility and efficient drug delivery. Specifically, a targeted drug delivery system based on lipid nanomaterials has inherited the advantage of optimum dosage and low side effects. In this review, insights on currently used potential lipid-based nanomaterials are collected and introduced. The review sheds light on conjugation, targeting, diagnosis, treatment, and clinical significance of lipid-based nanomaterials to treat breast cancer. Furthermore, a brighter side of lipid-based nanomaterials as future potential drug delivery systems for breast cancer therapy is discussed.

APA, Harvard, Vancouver, ISO, and other styles

30

Shirodkar, Rupesh K., Lalit Kumar, Srinivas Mutalik, and Shaila Lewis. "Solid Lipid Nanoparticles and Nanostructured Lipid Carriers: Emerging Lipid Based Drug Delivery Systems." Pharmaceutical Chemistry Journal 53, no. 5 (August 2019): 440–53. http://dx.doi.org/10.1007/s11094-019-02017-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Nishida, Koyo. "Recent Advances in Lipid-Based Drug Delivery." Pharmaceutics 13, no. 7 (June 22, 2021): 926. http://dx.doi.org/10.3390/pharmaceutics13070926.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Chime, Amarachi. "Lipid-based drug delivery systems (LDDS): Recent advances and applications of lipids in drug delivery." African Journal of Pharmacy and Pharmacology 7, no. 48 (December 29, 2013): 3034–59. http://dx.doi.org/10.5897/ajppx2013.0004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Haranath, Chinthaginjala. "Recent advances in lipid based nanovesicles for transdermal drug delivery." Journal of medical pharmaceutical and allied sciences 11, no. 6 (December 31, 2022): 5375–81. http://dx.doi.org/10.55522/jmpas.v11i6.4273.

Full text

Abstract:

Lipid based nanovesicles are the formulations which are used for the delivery of hydrophilic, hydrophobic and amphiphilic drugs or compounds. They are very helpful for the drugs which are hydrophilic and irritant drugs that can be encapsulated and delivered to the target site. They are very advantageous over conventional formulations. Lipid based nanovesicular systems will efficaciously help the drugs addressing the issues of solubility and penetration thereby promotes bioavailability. Now a days lipid based nanovesicles for transdermal delivery of drug has become very useful especially for hydrophilic drugs. The use of the nanovesicles for transdermal drug delivery will overcome the drawbacks associated with the route of drug delivery, such as oral and parenteral. Lipid based nanocarriers includes liposomes, transferosomes, ethosomes, niosomes, ufasomes, spinghosomes, pharmacosomes etc., This review article describes the types, formulation methods, evaluation and the research works done on lipid based nanovesicles for transdermal delivery of the drug.

APA, Harvard, Vancouver, ISO, and other styles

34

Quach, Hung, Tuong-Vi Le, Thanh-Thuy Nguyen, Phuong Nguyen, Cuu Khoa Nguyen, and Le Hang Dang. "Nano-Lipids Based on Ginger Oil and Lecithin as a Potential Drug Delivery System." Pharmaceutics 14, no. 8 (August 9, 2022): 1654. http://dx.doi.org/10.3390/pharmaceutics14081654.

Full text

Abstract:

Lipid nanoparticles based on lecithin are an interesting part of drug delivery systems. However, the stability of lecithin nano-lipids is problematic due to the degradation of lecithin, causing a decrease in pH. In this study, the modification of the conventional nano-lipid-based soybean lecithin was demonstrated. Ginger-oil-derived Zingiber officinale was used along with lecithin, cholesterol and span 80 to fabricate nano-lipids (GL nano-lipids) using a thin-film method. TEM and a confocal microscope were used to elucidate GL nano-lipids’ liposome-like morphology. The average size of the resultant nano-lipid was 249.1 nm with monodistribution (PDI = 0.021). The ζ potential of GL nano-lipids was negative, similarly to as-prepared nano-lipid-based lecithin. GL nano-lipid were highly stable over 60 days of storage at room temperature in terms of size and ζ potential. A shift in pH value from alkaline to acid was detected in lecithin nano-lipids, while with the incorporation of ginger oil, the pH value of nano-lipid dispersion was around 7.0. Furthermore, due to the richness of shogaol-6 and other active compounds in ginger oil, the GL nano-lipid was endowed with intrinsic antibacterial activity. In addition, the sulforhodamine B (SRB) assay and live/dead imaging revealed the excellent biocompatibility of GL nano-lipids. Notably, GL nano-lipids were capable of carrying hydrophobic compounds such as curcumin and performed a pH-dependent release profile. A subsequent characterization showed their suitable potential for drug delivery systems.

APA, Harvard, Vancouver, ISO, and other styles

35

Pandey, Vikas, and Seema Kohli. "Lipids and Surfactants: The Inside Story of Lipid-Based Drug Delivery Systems." Critical Reviews™ in Therapeutic Drug Carrier Systems 35, no. 2 (2018): 99–155. http://dx.doi.org/10.1615/critrevtherdrugcarriersyst.2018016710.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Aldosari, Basmah N., Iman M. Alfagih, and Alanood S. Almurshedi. "Lipid Nanoparticles as Delivery Systems for RNA-Based Vaccines." Pharmaceutics 13, no. 2 (February 2, 2021): 206. http://dx.doi.org/10.3390/pharmaceutics13020206.

Full text

Abstract:

There has been increased interest in the development of RNA-based vaccines for protection against various infectious diseases and also for cancer immunotherapies. Rapid and cost-effective manufacturing methods in addition to potent immune responses observed in preclinical and clinical studies have made mRNA-based vaccines promising alternatives to conventional vaccine technologies. However, efficient delivery of these vaccines requires that the mRNA be protected against extracellular degradation. Lipid nanoparticles (LNPs) have been extensively studied as non-viral vectors for the delivery of mRNA to target cells because of their relatively easy and scalable manufacturing processes. This review highlights key advances in the development of LNPs and reviews the application of mRNA-based vaccines formulated in LNPs for use against infectious diseases and cancer.

APA, Harvard, Vancouver, ISO, and other styles

37

Furneri, Pio Maria, Virginia Fuochi, and Rosario Pignatello. "Lipid-based Nanosized Delivery Systems for Fluoroquinolones: A Review." Current Pharmaceutical Design 23, no. 43 (February 15, 2018): 6696–704. http://dx.doi.org/10.2174/1381612823666171122110103.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Sistla, Ramakrishna. "Lipid-based delivery systems for biomedical and pharmaceutical applications." Chemistry and Physics of Lipids 238 (August 2021): 105104. http://dx.doi.org/10.1016/j.chemphyslip.2021.105104.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Semple, Sean C., Robert Leone, Christopher J. Barbosa, Ying K. Tam, and Paulo J. C. Lin. "Lipid Nanoparticle Delivery Systems to Enable mRNA-Based Therapeutics." Pharmaceutics 14, no. 2 (February 11, 2022): 398. http://dx.doi.org/10.3390/pharmaceutics14020398.

Full text

Abstract:

The world raced to develop vaccines to protect against the rapid spread of SARS-CoV-2 infection upon the recognition of COVID-19 as a global pandemic. A broad spectrum of candidates was evaluated, with mRNA-based vaccines emerging as leaders due to how quickly they were available for emergency use while providing a high level of efficacy. As a modular technology, the mRNA-based vaccines benefitted from decades of advancements in both mRNA and delivery technology prior to the current global pandemic. The fundamental lessons of the utility of mRNA as a therapeutic were pioneered by Dr. Katalin Kariko and her colleagues, perhaps most notably in collaboration with Drew Weissman at University of Pennsylvania, and this foundational work paved the way for the development of the first ever mRNA-based therapeutic authorized for human use, COMIRNATY®. In this Special Issue of Pharmaceutics, we will be honoring Dr. Kariko for her great contributions to the mRNA technology to treat diseases with unmet needs. In this review article, we will focus on the delivery platform, the lipid nanoparticle (LNP) carrier, which allowed the potential of mRNA therapeutics to be realized. Similar to the mRNA technology, the development of LNP systems has been ongoing for decades before culminating in the success of the first clinically approved siRNA-LNP product, ONPATTRO®, a treatment for an otherwise fatal genetic disease called transthyretin amyloidosis. Lessons learned from the siRNA-LNP experience enabled the translation into the mRNA platform with the eventual authorization and approval of the mRNA-LNP vaccines against COVID-19. This marks the beginning of mRNA-LNP as a pharmaceutical option to treat genetic diseases.

APA, Harvard, Vancouver, ISO, and other styles

40

Foged, Camilla. "siRNA Delivery with Lipid-based Systems: Promises and Pitfalls." Current Topics in Medicinal Chemistry 12, no. 2 (January 1, 2012): 97–107. http://dx.doi.org/10.2174/156802612798919141.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Wong, F. M. P., P. Harvie, Y. P. Zhang, E. C. Ramsay, and M. B. Bally. "Phosphatidylethanolamine mediated destabilization of lipid-based pDNA delivery systems." International Journal of Pharmaceutics 255, no. 1-2 (April 2003): 117–27. http://dx.doi.org/10.1016/s0378-5173(03)00051-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Fathi, Milad, M. R. Mozafari, and M. Mohebbi. "Nanoencapsulation of food ingredients using lipid based delivery systems." Trends in Food Science & Technology 23, no. 1 (January 2012): 13–27. http://dx.doi.org/10.1016/j.tifs.2011.08.003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Porter, Christopher J. H., Colin W. Pouton, Jean F. Cuine, and William N. Charman. "Enhancing intestinal drug solubilisation using lipid-based delivery systems." Advanced Drug Delivery Reviews 60, no. 6 (March 2008): 673–91. http://dx.doi.org/10.1016/j.addr.2007.10.014.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Davis, S. S. "Coming of age of lipid-based drug delivery systems." Advanced Drug Delivery Reviews 56, no. 9 (May 2004): 1241–42. http://dx.doi.org/10.1016/j.addr.2004.02.001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Efendy Goon, Danial, Siti Hamimah Sheikh Abdul Kadir, Normala Ab Latip, Sharaniza Ab. Rahim, and Musalmah Mazlan. "Palm Oil in Lipid-Based Formulations and Drug Delivery Systems." Biomolecules 9, no. 2 (February 13, 2019): 64. http://dx.doi.org/10.3390/biom9020064.

Full text

Abstract:

Palm oil is natural oil packed with important compounds and fatty acids ready to be exploited in lipid-based formulations and drug delivery. Palm oil and palm kernel oil contain long-chain and medium-chain triglycerides, respectively, including phytonutrients such as tocotrienol, tocopherol and carotenes. The exploitation of these compounds in a lipid-based formulation would be able to address hydrophobicity, lipophilicity, poor bioavailability and low water-solubility of many current drugs. The utilisation of palm oil as part of the drug delivery system seemed to improve the bioavailability and solubility of the drug, stabilising emulsification of formulation between emulsifier and surfactant, promoting enhanced drug permeability and performance, as well as extending the shelf-life of the drug. Despite the complexity in designing lipid-based formulations, palm oil has proven to offer dynamic behaviour in providing versatility in drug design, form and delivery. However, the knowledge and application of palm oil and its fractions in lipid-based formulation are scarce and interspersed. Therefore, this study aims to focus on the research and outcomes of using palm oil in lipid-based formulations and drug delivery systems, due to the importance of establishing its capabilities and benefits.

APA, Harvard, Vancouver, ISO, and other styles

46

Li, Ping, Hanne Mørck Nielsen, and Anette Müllertz. "Oral delivery of peptides and proteins using lipid-based drug delivery systems." Expert Opinion on Drug Delivery 9, no. 10 (August 17, 2012): 1289–304. http://dx.doi.org/10.1517/17425247.2012.717068.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Martel-Estrada, Santos-Adriana, Andrea-Isabel Morales-Cardona, Claudia-Lucía Vargas-Requena, Juan-Antonio Rubio-Lara, Carlos-Alberto Martínez-Pérez, and Florinda Jimenez-Vega. "Delivery systems in nanocosmeceuticals." REVIEWS ON ADVANCED MATERIALS SCIENCE 61, no. 1 (January 1, 2022): 901–30. http://dx.doi.org/10.1515/rams-2022-0282.

Full text

Abstract:

Abstract Today, the growth of the cosmetic industry and dramatic technological advances have led to the creation of functional cosmetical products that enhance beauty and health. Such products can be defined as topical cosmetic drugs to improve health and beauty functions or benefits. Implementing nanotechnology and advanced engineering in these products has enabled innovative product formulations and solutions. The search included organic molecules used as cosmeceuticals and nanoparticles (NPs) used in that field. As a result, this document analyses the use of organic and inorganic particles, metals, metal-oxides, and carbon-based particles. Additionally, this document includes lipid and nanoparticles solid lipid systems. In conclusion, using NPs as vehicles of active substances is a potential tool for transporting active ingredients. Finally, this review includes the nanoparticles used in cosmeceuticals while presenting the progress made and highlighting the hidden challenges associated with nanocosmeceuticals.

APA, Harvard, Vancouver, ISO, and other styles

48

Sahu, Suresh Kumar, Rakesh Raj, Pooja Mongia Raj, and Ram Alpana. "Topical Lipid Based Drug Delivery Systems for Skin Diseases: A Review." Current Drug Therapy 15, no. 4 (November 30, 2020): 283–98. http://dx.doi.org/10.2174/1574885513666181112153213.

Full text

Abstract:

Treatment of skin ailments through systemic administration is limited due to toxicity and patients discomfort. Hence, lower risk of systemic side effects from topical dosage forms like ointments, creams, emulsions and gels is more preferred for the treatment of skin disease. Application of lipid based carriers in drug delivery in topical formulations has recently become one of the major approaches to improve drug permeation, safety, and effectiveness. These delivery systems include liposomes, ethosomes, transfersomes, Nanoemulsions (NEs), Solid Lipid Nanoparticles (SLNs) Nanostructured Lipid Carriers (NLCs) and micelles. Most of the liposomes and SLNs based products are in the market while some are under investigation. Transcutaneous delivery of therapeutics to the skin layer by novel lipid based carriers has enhanced topical therapy for the treatment of skin ailments. This article covers an overview of the lipid-based carriers for topical uses to alleviate skin diseases.

APA, Harvard, Vancouver, ISO, and other styles

49

Farra, Rossella, Matea Maruna, Francesca Perrone, Mario Grassi, Fabio Benedetti, Marianna Maddaloni, Maguie El Boustani, et al. "Strategies for Delivery of siRNAs to Ovarian Cancer Cells." Pharmaceutics 11, no. 10 (October 22, 2019): 547. http://dx.doi.org/10.3390/pharmaceutics11100547.

Full text

Abstract:

The unmet need for novel therapeutic options for ovarian cancer (OC) deserves further investigation. Among the different novel drugs, small interfering RNAs (siRNAs) are particularly attractive because of their specificity of action and efficacy, as documented in many experimental setups. However, the fragility of these molecules in the biological environment necessitates the use of delivery materials able to protect them and possibly target them to the cancer cells. Among the different delivery materials, those based on polymers and lipids are considered very interesting because of their biocompatibility and ability to carry/deliver siRNAs. Despite these features, polymers and lipids need to be engineered to optimize their delivery properties for OC. In this review, we concentrated on the description of the therapeutic potential of siRNAs and polymer-/lipid-based delivery systems for OC. After a brief description of OC and siRNA features, we summarized the strategies employed to minimize siRNA delivery problems, the targeting strategies to OC, and the preclinical models available. Finally, we discussed the most interesting works published in the last three years about polymer-/lipid-based materials for siRNA delivery.

APA, Harvard, Vancouver, ISO, and other styles

50

Matei, Andreea-Mariana, Constantin Caruntu, Mircea Tampa, Simona Roxana Georgescu, Clara Matei, Maria Magdalena Constantin, Traian Vasile Constantin, et al. "Applications of Nanosized-Lipid-Based Drug Delivery Systems in Wound Care." Applied Sciences 11, no. 11 (May 27, 2021): 4915. http://dx.doi.org/10.3390/app11114915.

Full text

Abstract:

Impaired wound healing is an encumbering public health issue that increases the demand for developing new therapies in order to minimize health costs and enhance treatment efficacy. Available conventional therapies are still unable to maximize their potential in penetrating the skin at the target site and accelerating the healing process. Nanotechnology exhibits an excellent opportunity to enrich currently available medical treatments, enhance standard care and manage wounds. It is a promising approach, able to address issues such as the permeability and bioavailability of drugs with reduced stability or low water solubility. This paper focuses on nanosized-lipid-based drug delivery systems, describing their numerous applications in managing skin wounds. We also highlight the relationship between the physicochemical characteristics of nanosized, lipid-based drug delivery systems and their impact on the wound-healing process. Different types of nanosized-lipid-based drug delivery systems, such as vesicular systems and lipid nanoparticles, demonstrated better applicability and enhanced skin penetration in wound healing therapy compared with conventional treatments. Moreover, an improved chemically and physically stable drug delivery system, with increased drug loading capacity and enhanced bioavailability, has been shown in drugs encapsulated in lipid nanoparticles. Their applications in wound care show potential for overcoming impediments, such as the inadequate bioavailability of active agents with low solubility. Future research in nanosized-lipid-based drug delivery systems will allow the achievement of increased bioavailability and better control of drug release, providing the clinician with more effective therapies for wound care.

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!